

FOR IMMEDIATE RELEASE

February 22, 2011

Eisai Co., Ltd.
Sanko Junyaku Co., Ltd.

**Eisai, Sanko Junyaku Commence Co-promotion of DT-Navi,
a New Touch-Screen System to Help Physicians with ADAS-Jcog. Testing
and Assessment of Cognitive Function Change**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and its diagnostics subsidiary Sanko Junyaku Co., Ltd. (Headquarters: Tokyo, President & CEO: Keisuke Watanabe, "Sanko Junyaku") announced today that the two companies have commenced promotion of DT-Navi, a new touch-screen system to help physicians with ADAS-Jcog. testing and assessment of cognitive function change.

Developed by Nippon Tect Co., Ltd. (Headquarters: Tokyo, President & CEO: Iwao Masuoka), DT-Navi is a testing system that is used to aid physicians and other trained healthcare professionals when carrying out assessments using ADAS-Jcog. Sanko Junyaku also plans to launch a dedicated terminal for DT-Navi on February 1, 2011. DT-Navi requires that physicians receive specialized training.

By using the use of a touch screen, and by simply inputting necessary information as per the instructions, it automatically calculates test scores and provides physicians with test results. In determining the current cognitive function of a person with dementia, the system also makes predictions about future changes and is able to simulate the effects of treatment.

In addition to its use as a clinical psychological and neuropsychological assessment tool, DT-Navi is not only used to improve the performance of ADAS-Jcog. testing, it is also equipped with functions that help them with other tests, namely HDS-R, a simplified dementia screening test, and BEHAVE-AD, which assesses general symptoms of dementia based on information provided by caregivers.

In further fulfilling its corporate mission of *human health care (hhc)*, the Eisai Group established a new organizational structure in June 2010 to formulate and implement comprehensive strategies across its four Japan business segments comprising prescription pharmaceuticals, consumer products, diagnostics, and generics. Eisai also markets the Alzheimer's disease treatment

® as one of its core pharmaceutical products. By

[Notes to editors]

1. Product Outline

Touch Screen ADAS-Jcog. Diagnostic Testing System

3. Company Profiles

<Eisai Co., Ltd.>

Representative	Haruo Naito
Corporate Address	4-6-10 Koishikawa, Bunkyo-ku, Tokyo
Scope of Business	Research and development, manufacturing, marketing, and import and export of pharmaceuticals
Capital	44,985 million yen (as of September 30, 2010)

<Sanko Junyaku Co., Ltd.>

Representative	Keisuke Watanabe
Corporate Address	1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo
Scope of Business	Research and development, manufacturing, marketing, and import and export of in-vitro diagnostics, laboratory reagents, laboratory instruments and other supplies